Rutin phospholipid complexes confer neuroprotection in ischemic-stroke rats

Did your stroke hospital contact researchers to get this research going in humans? Once again there is that milquetoast word, 'neuroproection'  giving no sense of the immediate need to have it solved. It should be the neuronal cascade of death.

So when your doctor tells you they did nothing to stop the neuronal cascade of death, you can start screaming at them.

Do you prefer your hospital  incompetence NOT KNOWING? OR NOT DOING?

Rutin phospholipid complexes confer neuroprotection in ischemic-stroke rats

The title should be 'Rutin phospholipid complexes solved one of the pieces of the neuronal cascade of death in ischemic-stroke rats.' Which directly leads to; what other pieces need solving? And with proper followup we might actually get somewhere in solving stroke.

Issue 99, 2016, Issue in Progress

Hafsa Ahmad,^a   Abhishek Arya,^a   Satish Agrawal,^a   Prachi Mall,^a   Sheeba Saji Samuel,^b   Komal Sharma,^a   Pankaj Kumar Singh,^a   Sandeep Kumar Singh,^c   Guru Raghavendra Valicherla,^c   Kalyan Mitra,^d   Jiaur Rehman Gayen,^c   Sarvesh Paliwal,^e   Rakesh Shukla^b  and  Anil Kumar Dwivedi*^a  

Author affiliations

Abstract

Rutin, a natural flavonol glycoside is known to possess significant radical scavenging properties which might have beneficial effects in cerebral ischemia. However its oral administration and pharmaceutical use is limited due to its poor aqueous solubility and bioavailability. The current investigation aimed at development of rutin–phospholipid complexes (Ru–PLC's) and its characterization to provide neuro-protective effects in brain injury following stroke. Ru–PLC's were successfully fabricated and findings demonstrated improvement in bio-pharmaceutical properties on the basis of solubility, partition coefficient, dissolution profile, morphology, zeta potential, physical stability, FT-IR, DSC-TGA, forced degradation, photolytic degradation, ROS detection and oral pharmacokinetic studies. Ru–PLC's considerably improved functional outcomes in experimental stroke (MCAO model in rats) at a dose less than half of the effective dose of rutin. Effectiveness of treatment as evident from pharmaceutical properties as well as therapeutic activity was of the following order: Ru–EPLC > Ru–TPLC > rutin.